Ultime notizie per Nemaura Medical (OTC:NMRD) Azioni

Nemaura Medical

Nemaura Medical Inc is a medical technology company developing sugarBEAT as a non-invasive, affordable, and flexible Continuous Glucose Monitor (CGM) designed for people with diabetes and pre-diabetics to manage their glucose levels. Insulin users can adjunctively use sugarBEAT when calibrated with a finger-stick glucose reading. SugarBEAT consists of a daily disposable adhesive skin patch connected to a rechargeable transmitter with an app displaying glucose readings at five-minute intervals for periods up to 24 hours.

NEMAURA MEDICAL INC by Nemaura Medical, Inc.

Nemaura Medical Inc

Barclays analyst Betty Jiang maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Equal-Weight and lowers the price target from $30 to $27.

News

Price Target

Analyst Ratings

Barclays Maintains Equal-Weight on APA, Lowers Price Target to $27

RBC Capital analyst Rishi Jaluria maintains Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) with a Outperform and raises the price target from $250 to $275.

VEEV

RBC Capital Maintains Outperform on Veeva Systems, Raises Price Target to $275

Barclays analyst Mario Lu maintains Airbnb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABNB#NASDAQ">ABNB</a>) with a Underweight and raises the price target from $100 to $110.

ABNB

Barclays Maintains Underweight on Airbnb, Raises Price Target to $110

<a href="https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3" title="https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3">https://www.ft.com/content/de2ac6e1-c5ef-4b0a-aa70-c936c46fe9f3</a>

Legal

OTTR

'DoJ Investigates Potential Price-Fixing In PVC Pipe Market' - Financial Times

Editor&#8217;s note: This story has been updated with additional comments tweeted by Bill Ackman. 
Billionaires are lining up to serve in President-elect Donald Trump&#8216;s <a href="https://www.benzinga.com/news/24/11/41768178/donald-trump-defeats-kamala-harris-to-win-2024-election">incoming administration</a>, especially those eager to <a href="https://www.benzinga.com/news/24/08/40146910/does-donald-trumps-proposed-tax-cut-threaten-social-security-and-medicare-heres-what-think-tanks-war">cut federal assistance programs</a>.
Bill Ackman is one of them. 
On Friday morning, when a user on X asked whether the Pershing Square Capital founder would &#8220;consider joining Elon [Musk] in the Department of Government Efficiency,&#8221; Ackman <a href="https://x.com/BillAckman/status/1854891084381377017">replied</a> with a single word: &#8220;Yes.&#8221;
Musk has proposed the idea of creating a &#8220;Department of Government Efficiency.&#8221; This hypothetical agency would slash federal spending by the trillions. Should such a plan come to fruition, analysts suggest programs like health care, food security and housing <a href="https://www.benzinga.com/startups/24/11/41750727/kevin-oleary-supports-elon-musks-2-trillion-plan-to-slash-government-spending-with-trumps-backing-it">would be gutted</a>. 
Trump was receptive to this idea. 
See Also: <a href="https://www.benzinga.com/news/24/07/39657200/ex-trump-staffer-shares-texts-to-prove-that-ex-presidents-campaign-settled-to-keep-discrimination-an">Ex-Trump Staffer Shares Texts To Prove That Ex-President&#8217;s Campaign Settled To Keep Sexual Harassment Lawsuits Quiet</a>
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Yes
&mdash; Bill Ackman (@BillAckman) <a href="https://twitter.com/BillAckman/status/1854891084381377017?ref_src=twsrc%5Etfw">November 8, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Ackman is among Trump&#8217;s most ardent Wall Steet supporters. The billionaire told CNBC that he&#8217;s unfazed by the <a href="https://www.benzinga.com/government/24/11/41828468/trump-says-hed-replace-income-taxes-with-tariffs-the-potential-economic-fallout">potential market implications</a> of a second Trump administration.
In a follow-up tweet, Ackman said he is not leaving his day job for one with the Trump administration.
&#8220;Like Elon Musk who has a half a dozen full-time jobs, I would be delighted to help anyway that I can to help DOGE succeed,&#8221; Ackman tweeted. 
Musk contributed nine-digit sums to Trump&#8217;s campaign and organized much of Trump&#8217;s ground game.
The Tesla Inc. CEO has also openly said Americans will experience &#8220;temporary hardship&#8221; once federal cuts are made.
According to the U.S. Treasury, the country&#8217;s federal budget was $6.75 trillion in 2024. Musk&#8217;s proposal to make large cuts to the federal budget would necessitate shedding several categories. Analysts put social security, military spending, Medicare, and veterans benefits on that list.
It remains to be seen how high of a legislative priority this will be for Trump.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41843182/fed-cuts-rates-but-inflation-remains-elephant-in-the-room">Fed Cuts Interest Rates, But Inflation Remains Elephant In The Room</a></li>
</ul>
Image: Shutterstock

Government

Health Care

Politics

Bill Ackman Says He'd Consider Joining Elon Musk's 'Department Of Government Efficiency' Under Trump (UPDATED)

XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) shares are trading relatively flat on Friday after the company <a href="https://www.benzinga.com/pressreleases/24/11/g41841998/xpeng-unveils-the-p7-worlds-first-ai-defined-vehicle-redefining-premium-and-intelligent-driving">hosted its XPENG AI Day event.</a>
According to&nbsp;<a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>, XPEV stock has lost over 11% in the past year. Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Kensho Smart Mobility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAIL#NYSE">HAIL</a>).
On November 7, the company officially launched the XPENG P7+, <a href="https://www.benzinga.com/pressreleases/24/11/g41843762/xpeng-unveils-kunpeng-super-electric-system-and-ai-defined-mobility-innovations-at-xpeng-ai-day">the world&#8217;s first AI-defined vehicle, in China.</a>
XPeng has also launched the Kunpeng Super Electric System, an advanced 800V high-voltage platform with &#8220;ultra-fast&#8221; charging and AI-powered optimization. 
The system has a 430 km pure electric range and over 1,400 km combined range, with the ability to add 1 km of range per second during charging, per a press release.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/24/11/41846732/kars-etf-hits-golden-cross-powered-by-tesla-geely-xpeng-li">KARS ETF Hits Golden Cross Powered By Tesla, Geely, Xpeng, Li</a>
XPeng said that the system includes an &#8220;ultra-quiet&#8221; range extender and a battery management system that extends lifespan by 30%.
These apart, XPeng also unveiled major advancements in autonomous driving, flying cars, and AI robotics. The company's Ultra model Robotaxi features L4-level autonomy, Turing chips, and 3,000T of processing power.
The XPeng AEROHT flying car is a modular design with simple controls, set for its first public flight in November and pre-orders in December.
Additionally, XPeng&#8217;s AI Robot Iron, a humanoid robot with over 60 joints, is already in use for internal operations like factories and stores.
Chairman He Xiaopeng highlighted XPeng&#8217;s commitment to AI innovation as a key factor in driving future mobility.
Price Action: XPEV shares are trading lower by 0.11 to $14.21 at last check Friday.
Photo by Koshiro K on Shutterstock
Read Also:&nbsp;
<a href="https://www.benzinga.com/news/24/01/36508540/what-does-gms-electric-future-look-like-after-chevrolet-bolts-exit-last-years-delivery-numbers-could" target="_blank" rel="noreferrer noopener">What Does GM's Electric Future Look Like After Chevrolet Bolt's Exit? Last Year's Delivery Numbers Could Give A Hint</a>

Equities

Markets

Movers

General

HAIL

XPEV

What's Going On With XPeng Stock Friday?

Raymond James analyst Brian Peterson maintains RingCentral (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RNG#NYSE">RNG</a>) with a Strong Buy and lowers the price target from $52 to $50.

Raymond James Maintains Strong Buy on RingCentral, Lowers Price Target to $50

Barclays analyst Duffy Fischer maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Equal-Weight and raises the price target from $295 to $315.

Barclays Maintains Equal-Weight on Air Products & Chemicals, Raises Price Target to $315

RBC Capital analyst Daniel Perlin maintains Toast (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>) with a Sector Perform and raises the price target from $27 to $40.

TOST

RBC Capital Maintains Sector Perform on Toast, Raises Price Target to $40

Raymond James analyst Rick Patel maintains Ralph Lauren (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RL#NYSE">RL</a>) with a Outperform and raises the price target from $215 to $235.

Raymond James Maintains Outperform on Ralph Lauren, Raises Price Target to $235

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside &#8211; Here&#8217;s Why
Stephens analyst has initiated coverage on ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage oncology-focused biotechnology company developing antibody-drug conjugates (ADCs) for patients with hematological malignancies and solid tumors.
The company's lead asset, Zynlonta (loncastuximab tesirine-Ipyl), is a CD19-directed ADC with a pyrrolobenzodiazepine (PBD) payload.
The drug received accelerated FDA approval in January 2021 for adult patients with relapsed/refractory (r/r) large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.
Also Read:&nbsp;<a href="https://www.benzinga.com/general/biotech/23/07/33324772/adc-therapeutics-pulls-plug-on-mid-stage-zynlonta-study-in-untreated-lymphoma-patients-after-pati">ADC Therapeutics Pulls Plug On Mid-Stage Zynlonta Study In Untreated Lymphoma Patients After Patient Deaths</a>
The analyst points out that Zynlonta has faced stiff competition, and while it reached an annualized revenue run rate of about $80 million at its peak in the first quarter of 2023, it has struggled in the market.
The analyst expects Zynlonta&#8217;s peak revenue in the third-line treatment setting to reach $110 million in the U.S. by 2032.
The analyst&#8217;s outlook depends on the expectation that Zynlonta will receive approval for use in second-line treatment for diffuse large B-cell lymphoma (DLBCL), based on positive results from the LOTIS-5 and LOTIS-7 clinical trials.
Preclinical data suggests that combining Zynlonta with rituximab, an anti-CD20 antibody, may improve tumor control and provide longer-lasting results. The company is looking to expand Zynlonta&#8217;s use to treat second-line DLBCL and indolent lymphomas, either alone or in combination with other treatments.
Although the analyst supports Zynlonta's approval for second-line DLBCL, they are cautious about its revenue potential in this space.
Stephens has initiated with an Overweight rating, <a href="https://www.benzinga.com/quote/ADCT/analyst-ratings">with a price target of $6</a>.
The second-line DLBCL market is competitive with many treatment options available. However, the analyst sees value in Zynlonta due to its promising efficacy, with an 80% overall response rate and a 50% complete response rate. They estimate that Zynlonta could contribute about $172 million in revenue from second-line DLBCL by 2032.
In addition, ADCT has a broad pipeline of antibody-drug conjugates (ADCs) targeting other solid tumor indications, giving the company multiple opportunities for growth outside of Zynlonta.
Price Action: ADCT stock is up 0.68% at $2.95 at the last check on Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/24/11/41845345/baxter-expects-hurricane-helene-aftermath-to-impact-near-term-financial-outlook">Baxter Expects Hurricane Helene Aftermath To Impact Near-Term Financial Outlook</a></li>
</ul>

Analyst Color

Biotech

Initiation

Trading Ideas

ADCT

ADC Therapeutics Faces Competitive Oncology Market But Analyst Sees 100% Upside - Here's Why

Barclays analyst Matt Miksic maintains Tandem Diabetes Care (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) with a Overweight and raises the price target from $58 to $60.

TNDM

Barclays Maintains Overweight on Tandem Diabetes Care, Raises Price Target to $60

Barclays analyst Andrew Mok maintains Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) with a Equal-Weight and raises the price target from $19 to $21.

PRVA

Barclays Maintains Equal-Weight on Privia Health Gr, Raises Price Target to $21

Raymond James analyst Joseph Altobello maintains Planet Fitness (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLNT#NYSE">PLNT</a>) with a Strong Buy and raises the price target from $92 to $110.

PLNT

Raymond James Maintains Strong Buy on Planet Fitness, Raises Price Target to $110

Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) stock soared Friday after President-elect Donald Trump said he has no plans to sell his stake in the Truth Social parent.
Trump denied rumors of a potential share sale in a post on Truth Social, calling them "fake, untrue, and probably illegal," likely spread by market manipulators or short sellers. He emphasized, "I have no intention of selling."
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="553" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-1024x553.png" alt="" class="wp-image-638169" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-1024x553.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-768x415.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth-1536x829.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/08122722/Trump-Truth.png 1850w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Shares of the company were trading 16.23% higher to $32.19 midday Friday. 
Also Read: <a href="https://www.benzinga.com/government/regulations/24/11/41845483/taiwan-semiconductor-us-expansion-plans-unfazed-by-trump-win-report">Taiwan Semiconductor US Expansion Plans Unfazed by Trump Win: Report</a>
Trump Media stock plunged 23% Thursday. The sharp decline followed a 6% surge the previous day, driven by Trump's political return, according to Reuters. 
On Tuesday, Trump Media reported a <a href="https://www.benzinga.com/news/earnings/24/11/41760961/djt-stock-volatile-on-election-day-donald-trumps-media-company-reports-q3-earnings-growth-initiativ">third-quarter net sales</a> decline of 6% to $1.01 million. The company said advertising on the Truth Social platform drove the topline.
The company reported a loss of 10 cents per share compared to a loss of 30 cents per share in last year&#8217;s third quarter.
Despite recent losses and low revenue, Trump Media's market cap now exceeds $5.5 billion.
Trump Media stock has gained 75% year-to-date, gaining traction from Trump&#8217;s decision to hold onto <a href="https://www.benzinga.com/government/24/10/41606911/whats-going-on-with-trump-media-technology-stock-on-tuesday">his majority stake</a> in the company despite the expiry of the lockup period and his improving position as a presidential candidate running against Vice President Kamala Harris. 
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41844770/madison-square-garden-q1-revenue-drops-concerts-impress">Madison Square Garden Q1: Revenue Drops, Concerts Impress</a></li>
</ul>
Photo via Shutterstock.

Media

Trump Says He Won't Sell Trump Media Stock

<a href="https://news.bloomberglaw.com/health-law-and-business/american-jetblue-alliance-breakup-upheld-by-appeals-court">https://news.bloomberglaw.com/health-law-and-business/american-jetblue-alliance-breakup-upheld-by-appeals-court</a>
<ul>
<li>Decision affirms ruling that ended airline partnership</li>
<li>American Airlines had appealed, arguing court misapplied law</li>
</ul>
A partnership between American Airlines Group Inc. and JetBlue Airways Corp. violated US antitrust law, an appeals court ruled, affirming a lower court decision to end the alliance.
In a unanimous <a href="https://assets.bwbx.io/documents/users/iqjWHBFdfxIU/rXwJ_Vy85PrU/v0">decision</a>, a three-judge panel on the 1st US Circuit Court of Appeals in Boston said Friday that the airline alliance harmed consumers by reducing their choices for flights from airports in the Northeast US including New York City.
"Presented with an arrangement that had many of the essential attributes of an agreement between two powerful competitors sharing revenues and divvying up highly concentrated markets, the district court conducted ...
 &nbsp;

JBLU

'American-JetBlue Alliance Breakup Upheld By Appeals Court' - Bloomberg Law

Raymond James analyst Aaron Kessler maintains Pinterest (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINS#NYSE">PINS</a>) with a Outperform and lowers the price target from $40 to $34.

PINS

Raymond James Maintains Outperform on Pinterest, Lowers Price Target to $34

Barclays analyst Benjamin Budish maintains Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) with a Overweight and raises the price target from $30 to $32.

Barclays Maintains Overweight on Marex Group, Raises Price Target to $32

Analysts' ratings for APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) over the last quarter vary from bullish to bearish, as provided by 20 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for APA, presenting an average target of $35.6, a high estimate of $52.00, and a low estimate of $26.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 9.07%. 
<img src="https://www.benzinga.com/files/images/story/2024/1731089448_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive APA. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$33.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$48.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$28.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Paul Cheng</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$27.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$36.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Neil Mehta</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Sell</td>
<td>$26.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$47.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>In-Line</td>
<td>$33.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Neal Dingmann</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$34.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Josh Silverstein</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>William Janela</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$28.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$27.00</td>
<td>$36.00</td>
</tr>
<tr>
<td>Stephen Richardson</td>
<td>Evercore ISI Group</td>
<td>Maintains</td>
<td>In-Line</td>
<td>$39.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Betty Jiang</td>
<td>Barclays</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$35.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Scott Hanold</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$41.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Biju Perincheril</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$52.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Mark Lear</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$29.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Roger Read</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$49.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to APA. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of APA compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for APA's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of APA's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/APA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on APA analyst ratings.</a>
<h2>About APA</h2>
Based in Houston, APA is an independent exploration and production company. It operates primarily in the US, Egypt, the North Sea, and Suriname. At year-end 2023, proved reserves totaled 807 million barrels of oil equivalent, with net reported production of 405 thousand boe/day that year (64% of which was oil and natural gas liquids, with the remainder natural gas).
<h3>Financial Milestones: APA's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Positive Revenue Trend: Examining APA's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 41.59% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Energy sector.
Net Margin: APA's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 21.27% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): APA's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 13.47%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): APA's ROA stands out, surpassing industry averages. With an impressive ROA of 3.08%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: APA's debt-to-equity ratio surpasses industry norms, standing at 1.26. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On APA Through 20 Analysts

AAON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $132.25, along with a high estimate of $150.00 and a low estimate of $111.00. Observing a 14.67% increase, the current average has risen from the previous average price target of $115.33. 
<img src="https://www.benzinga.com/files/images/story/2024/1731089431_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive AAON. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Julio Romero</td>
<td>Sidoti &amp; Co.</td>
<td>Announces</td>
<td>Neutral</td>
<td>$111.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AAON. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AAON compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of AAON's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Capture valuable insights into AAON's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AAON/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AAON analyst ratings.</a>
<h2>Delving into AAON's Background</h2>
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. AAON's products serve the commercial and industrial new construction and replacement markets, primarily in North America.
<h3>AAON: A Financial Overview</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: AAON's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 10.43%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Industrials sector.
Net Margin: AAON's net margin is impressive, surpassing industry averages. With a net margin of 16.66%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): AAON's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 6.85%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.32%, the company showcases effective utilization of assets.
Debt Management: AAON's debt-to-equity ratio is below the industry average. With a ratio of 0.14, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAON

Peeling Back The Layers: Exploring AAON Through Analyst Insights

Nemaura Medical secures $10M non-dilutive credit facility

Nemaura Medical receives positive Nasdaq listing decision

Ascendiant analyst Edward Woo maintained a Buy rating on Nemaura Medical (NMRD – Research Report) on December 15 and set a price target of $3.50. E...

Buy Rating Affirmed for Nemaura Medical on sugarBEAT Prospects and Market Expansion

Nemaura Medical Inc (NMRD) has issued an update. Nemaura Medical Inc. has engaged in significant financial restructuring, converting a $314,000 out...

Nemaura Medical Restructures Finances, Board Members Change

Nemaura Medical ( ($NMRD) ) has shared an update. Nemaura Medical Inc. has streamlined operations by outsourcing most of its manufacturing and is i...

Comments

Nemaura Medical

Notizie

Ultime notizie per Nemaura Medical (OTC:NMRD) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO